Candel Therapeutics, Inc. Share Price & Technical Analysis
CADL · $7.99 (+0.76%)
Healthcare / Biotechnology
$7.99
+0.76%
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of r…
Price chart
Seasonality
May has 5 positive and 0 negative years (last 5 years shown)
29% return in May, 21% avg return in past 3 year May month.
43% return in 2026, 137% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 2% | -10% | -4% | 27% | 29% | – | – | – | – | – | – | – | 43% |
| 25 | -17% | 32% | -37% | -12% | 10% | -7% | 31% | -8% | -12% | 8% | -9% | 21% | -1% |
| 24 | -13% | 36% | -16% | 318% | 27% | -31% | -5% | 15% | 0% | -23% | -11% | 85% | 381% |
| 23 | 44% | -31% | -30% | -7% | 25% | -13% | -8% | 20% | -25% | -10% | 0% | 67% | 32% |
| 22 | -43% | -9% | 24% | -31% | 9% | -9% | -3% | 9% | -9% | -39% | 0% | 0% | -100% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$619.50M
P/E ratio
—
52W high
$9.27
52W low
$4.35
Volume
15,87,625
Beta
-0.58
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Candel Therapeutics, Inc. share price today?
- Candel Therapeutics, Inc. (CADL) last traded around $7.99 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CADL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CADL. Download the app for real-time alerts.
- How can I analyze Candel Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.